Relevant publications LMMO

Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.
Noeparast A, Teugels E, Giron P, Verschelden G, De Brakeleer S, Decoster L, De Grève J. Oncotarget. 2016 Aug 26;8(36):60094-60108.

 

Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2.
Ren Z, Aerts JL, Vandenplas H, Wang JA, Gorbenko O, Chen JP, Giron P, Heirman C, Goyvaerts C, Zacksenhaus E, Minden MD, Stambolic V, Breckpot K, De Grève J. Cell Death Dis. 2016 Dec 22;7(12):e2560.

 

Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).
De Grève J, Van Meerbeeck J, Vansteenkiste JF, Decoster L, Meert AP, Vuylsteke P, Focan C, Canon JL, Humblet Y, Berchem G, Colinet B, Galdermans D, Bosquée L, Vermeij J, Dewaele A, Geers C, Schallier D, Teugels E. PLoS One. 2016 Mar 31;11(3):e0147599.

 

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
Umelo IA, De Wever O, Kronenberger P, Van Deun J, Noor A, Singh K, Teugels E, Chen G, Bracke M, De Grève J. Oncotarget. 2015 Aug 21;6(24):20132-44.

 

Whole-genome landscape of pancreatic neuroendocrine tumours.
Scarpa A, Chang DK, Nones K,…Rooman I et al. Nature. 2017 Mar 2;543(7643):65-71.


Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions.
Pinho AV, Mawson A, Gill A, Arshi M, Warmerdam M, Giry-Laterriere M, Eling N, Lie T, Kuster E, Camargo S, Biankin AV, Wu J, Rooman I. Oncotarget. 2016 Nov 15;7(46):74768-74778.

 

More publications:

https://www.ncbi.nlm.nih.gov/pubmed/?term=De+Greve+J;

https://www.ncbi.nlm.nih.gov/pubmed/?term=Rooman+I